Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y6S9

UPID:
RPKL1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9Y6S9; A6NGM9; Q69YT9; Q6ZMQ6; Q96NR9; Q9BSU9

BACKGROUND:
The Ribosomal protein S6 kinase-like 1, with the unique identifier Q9Y6S9, is integral to cellular signaling mechanisms. It belongs to a larger family of kinases that are essential for cell cycle regulation and response to growth factors. By phosphorylating key substrates, it modulates various biological processes, including mRNA translation and cellular metabolism.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ribosomal protein S6 kinase-like 1 holds promise for uncovering novel therapeutic avenues. Given its significant role in controlling cellular processes critical for growth and survival, targeting this kinase could lead to innovative treatments for conditions marked by dysregulated cell proliferation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.